BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 17664350)

  • 1. Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion.
    Léon C; Eckly A; Hechler B; Aleil B; Freund M; Ravanat C; Jourdain M; Nonne C; Weber J; Tiedt R; Gratacap MP; Severin S; Cazenave JP; Lanza F; Skoda R; Gachet C
    Blood; 2007 Nov; 110(9):3183-91. PubMed ID: 17664350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal megakaryocyte morphology and proplatelet formation in mice with megakaryocyte-restricted MYH9 inactivation.
    Eckly A; Strassel C; Freund M; Cazenave JP; Lanza F; Gachet C; Léon C
    Blood; 2009 Apr; 113(14):3182-9. PubMed ID: 18984861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proplatelet formation deficit and megakaryocyte death contribute to thrombocytopenia in Myh9 knockout mice.
    Eckly A; Rinckel JY; Laeuffer P; Cazenave JP; Lanza F; Gachet C; Léon C
    J Thromb Haemost; 2010 Oct; 8(10):2243-51. PubMed ID: 20695978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Romiplostim administration shows reduced megakaryocyte response-capacity and increased myelofibrosis in a mouse model of MYH9-RD.
    Léon C; Evert K; Dombrowski F; Pertuy F; Eckly A; Laeuffer P; Gachet C; Greinacher A
    Blood; 2012 Apr; 119(14):3333-41. PubMed ID: 22234693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myosin IIA is critical for organelle distribution and F-actin organization in megakaryocytes and platelets.
    Pertuy F; Eckly A; Weber J; Proamer F; Rinckel JY; Lanza F; Gachet C; Léon C
    Blood; 2014 Feb; 123(8):1261-9. PubMed ID: 24243973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Megakaryocyte migration defects due to nonmuscle myosin IIA mutations underlie thrombocytopenia in MYH9-related disease.
    Pal K; Nowak R; Billington N; Liu R; Ghosh A; Sellers JR; Fowler VM
    Blood; 2020 May; 135(21):1887-1898. PubMed ID: 32315395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered cytoskeleton organization in platelets from patients with MYH9-related disease.
    Canobbio I; Noris P; Pecci A; Balduini A; Balduini CL; Torti M
    J Thromb Haemost; 2005 May; 3(5):1026-35. PubMed ID: 15869600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myosin-II repression favors pre/proplatelets but shear activation generates platelets and fails in macrothrombocytopenia.
    Spinler KR; Shin JW; Lambert MP; Discher DE
    Blood; 2015 Jan; 125(3):525-33. PubMed ID: 25395423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A.
    Zhang Y; Conti MA; Malide D; Dong F; Wang A; Shmist YA; Liu C; Zerfas P; Daniels MP; Chan CC; Kozin E; Kachar B; Kelley MJ; Kopp JB; Adelstein RS
    Blood; 2012 Jan; 119(1):238-50. PubMed ID: 21908426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The abnormal proplatelet formation in MYH9-related macrothrombocytopenia results from an increased actomyosin contractility and is rescued by myosin IIA inhibition.
    Chen Y; Boukour S; Milloud R; Favier R; Saposnik B; Schlegel N; Nurden A; Raslova H; Vainchenker W; Balland M; Nurden P; Debili N
    J Thromb Haemost; 2013 Dec; 11(12):2163-75. PubMed ID: 24165359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defective VWF secretion due to expression of MYH9-RD E1841K mutant in endothelial cells disrupts hemostasis.
    Cao Y; Sun Y; Deng Y; Wei G; Liu J; Jin S; Dong C; Kang X; Huo Y; Zhang J; Luo J
    Blood Adv; 2022 Aug; 6(15):4537-4552. PubMed ID: 35764499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of mouse model of MYH9 disorders: heterozygous R702C mutation provokes macrothrombocytopenia with leukocyte inclusion bodies, renal glomerulosclerosis and hearing disability.
    Suzuki N; Kunishima S; Ikejiri M; Maruyama S; Sone M; Takagi A; Ikawa M; Okabe M; Kojima T; Saito H; Naoe T; Matsushita T
    PLoS One; 2013; 8(8):e71187. PubMed ID: 23976996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Megakaryocytes of patients with MYH9-related thrombocytopenia present an altered proplatelet formation.
    Pecci A; Malara A; Badalucco S; Bozzi V; Torti M; Balduini CL; Balduini A
    Thromb Haemost; 2009 Jul; 102(1):90-6. PubMed ID: 19572073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Megakaryocyte-specific RhoA deficiency causes macrothrombocytopenia and defective platelet activation in hemostasis and thrombosis.
    Pleines I; Hagedorn I; Gupta S; May F; Chakarova L; van Hengel J; Offermanns S; Krohne G; Kleinschnitz C; Brakebusch C; Nieswandt B
    Blood; 2012 Jan; 119(4):1054-63. PubMed ID: 22045984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Megakaryocyte and platelet abnormalities in a patient with a W33C mutation in the conserved SH3-like domain of myosin heavy chain IIA.
    Kahr WH; Savoia A; Pluthero FG; Li L; Christensen H; De Rocco D; Traivaree C; Butchart SE; Curtin J; Stollar EJ; Forman-Kay JD; Blanchette VS
    Thromb Haemost; 2009 Dec; 102(6):1241-50. PubMed ID: 19967157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a fibrin-independent platelet contractile mechanism regulating primary hemostasis and thrombus growth.
    Ono A; Westein E; Hsiao S; Nesbitt WS; Hamilton JR; Schoenwaelder SM; Jackson SP
    Blood; 2008 Jul; 112(1):90-9. PubMed ID: 18310501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations responsible for MYH9-related thrombocytopenia impair SDF-1-driven migration of megakaryoblastic cells.
    Pecci A; Bozzi V; Panza E; Barozzi S; Gruppi C; Seri M; Balduini CL
    Thromb Haemost; 2011 Oct; 106(4):693-704. PubMed ID: 21833445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-muscle myosin heavy chain IIA and IIB interact and co-localize in living cells: relevance for MYH9-related disease.
    Marini M; Bruschi M; Pecci A; Romagnoli R; Musante L; Candiano G; Ghiggeri GM; Balduini C; Seri M; Ravazzolo R
    Int J Mol Med; 2006 May; 17(5):729-36. PubMed ID: 16596254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes.
    Heath KE; Campos-Barros A; Toren A; Rozenfeld-Granot G; Carlsson LE; Savige J; Denison JC; Gregory MC; White JG; Barker DF; Greinacher A; Epstein CJ; Glucksman MJ; Martignetti JA
    Am J Hum Genet; 2001 Nov; 69(5):1033-45. PubMed ID: 11590545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYH9: Structure, functions and role of non-muscle myosin IIA in human disease.
    Pecci A; Ma X; Savoia A; Adelstein RS
    Gene; 2018 Jul; 664():152-167. PubMed ID: 29679756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.